|
EP2153234A2
|
|
Methods for early diagnosis of kidney disease
|
|
WO2008033455A2
|
|
Biphenyl and heteroaryl phenyl derivatives as protein tyrosine phosphatases inhibitors
|
|
WO2008033932A2
|
|
Biarylthiazole carboxylic acid derivatives as protein tyrosine phosphatase-ib inhibitors
|
|
WO2008033931A1
|
|
Para-xylylene carboxylic acids and isothiazolones useful as protein tyrosine phosphatases (ptps) in particular ptp-ib
|
|
WO2008033934A1
|
|
Substituted heteroaryl carboxylic acid derivatives as ptb-1b inhibitors
|
|
EP1844043A2
|
|
Heterocycle substituted carboxylic acids for the treatment of diabetes
|
|
EP1814869A2
|
|
Substituted amino acids as protein tyrosine phosphatase inhibitors
|
|
CA2587566A1
|
|
Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
|
|
EP1805159A1
|
|
Substituted carboxylic acids
|
|
EP1805136A1
|
|
Substituted phenylalkanoic acids
|
|
MXPA05011523A
|
|
Substituted heteroaryls as inhibitors of protein tyrosine phosphatases.
|
|
EP1622886A2
|
|
Substituted amino carboxylic acids as inhibitors of protein tyrosine phosphatase-1b
|
|
MXPA05011539A
|
|
Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b.
|
|
MXPA05010937A
|
|
Substituted phenylalkanoic acids.
|
|
CA2523714A1
|
|
Substituted carboxylic acids
|
|
KR20050026002A
|
|
Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications
|
|
AU2002365889A1
|
|
Regulated expression of recombinant dna
|
|
CA2395871A1
|
|
Substituted indolealkanoic acids derivatives and formulations containing same for use in treatment of diabetic complications
|
|
MXPA02007293A
|
|
Substituted indolalkanoic acids derivates and formulations containing the same to be used in the treatment of diabetic complications.
|
|
AU3278501A
|
|
Methods for lowering uric acid levels
|
